Daobin Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daobin Cheng has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Bing Han
Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
1 shared publicationChao Qin
Department of Neurology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China
1 shared publication- Chao Qin
Department of Neurology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China
1 shared publication - Chao Xiao
Department of Neurology The First Affiliated Hospital of Guangxi Medical University Nanning Guangxi China
1 shared publication - Chunxiao Jie
Department of Neurology The First Affiliated Hospital of Guangxi Medical University Nanning Guangxi China
1 shared publication - Chunyong Chen
Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
Protein lactylation in atherosclerosis – Mechanisms and therapeutic potential: A narrative review
Protein lactylation, which links cellular metabolism to gene regulation and protein function, may influence atherosclerosis. This narrative review explores its cellular mechanisms and therapeutic potential. We searched PubMed from inception to September 30, 2026, for English-language studies and reviews. The synthesis differentiated lactylation from lactate signaling and distinguished direct evidence in atherosclerosis from findings in other disease models. Predominantly preclinical evidence suggests that both histone and non-histone lactylation are involved in endothelial inflammation, endothelial-to-mesenchymal transition, macrophage polarization and ferroptosis, and vascular smooth muscle cell senescence, phenotypic remodeling, and calcification. Depending on the cellular context, modification site, and downstream targets, lactylation can either promote vascular injury or support anti-inflammatory responses and plaque stabilization. Candidate interventions target lactate production, transport, and lactylation-related enzymes, but their effects often lack specificity for lactylation. Much of the therapeutic evidence originates from non-atherosclerotic models, and clinical validation is currently absent. Therefore, therapeutic development should consider cell type, disease stage, and modification site, with validation of causal mechanisms, selectivity, and safety in atherosclerosis models prior to clinical translation.
- 22 October 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
Open AccessProtein lactylation in atherosclerosis – Mechanisms and therapeutic potential: A narrative review
Protein lactylation, which links cellular metabolism to gene regulation and protein function, may influence atherosclerosis. This narrative review explores its cellular mechanisms and therapeutic potential. We searched PubMed from inception to September 30, 2026, for English-language studies and reviews. The synthesis differentiated lactylation from lactate signaling and distinguished direct evidence in atherosclerosis from findings in other disease models. Predominantly preclinical evidence suggests that both histone and non-histone lactylation are involved in endothelial inflammation, endothelial-to-mesenchymal transition, macrophage polarization and ferroptosis, and vascular smooth muscle cell senescence, phenotypic remodeling, and calcification. Depending on the cellular context, modification site, and downstream targets, lactylation can either promote vascular injury or support anti-inflammatory responses and plaque stabilization. Candidate interventions target lactate production, transport, and lactylation-related enzymes, but their effects often lack specificity for lactylation. Much of the therapeutic evidence originates from non-atherosclerotic models, and clinical validation is currently absent. Therefore, therapeutic development should consider cell type, disease stage, and modification site, with validation of causal mechanisms, selectivity, and safety in atherosclerosis models prior to clinical translation.
- Top Cited PapersOpen Access
- 25 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e035558
Piezo1‐Mediated Mechanotransduction Contributes to Disturbed Flow‐Induced Atherosclerotic Endothelial Inflammation
Background: Disturbed flow generates oscillatory shear stress (OSS), which in turn leads to endothelial inflammation and atherosclerosis. Piezo1, a biomechanical force sensor, plays a crucial role in the cardiovascular system. However, the specific role of Piezo1 in atherosclerosis remains to be fully elucidated. Methods and Results: We detected the expression of Piezo1 in atherosclerotic mice and endothelial cells from regions with disturbed blood flow. The pharmacological inhibitor Piezo1 inhibitor (GsMTx4) was used to evaluate the impact of Piezo1 on plaque progression and endothelial inflammation. We examined Piezo1's direct response to OSS in vitro and its effects on endothelial inflammation. Furthermore, mechanistic studies were conducted to explore the potential molecular cascade through which Piezo1 mediates endothelial inflammation in response to OSS. Our findings revealed the upregulation of Piezo1 in apoE−/− (apolipoprotein E) atherosclerotic mice, which is associated with disturbed flow. Treatment with GsMTx4 not only delayed plaque progression but also mitigated endothelial inflammation in both chronic and disturbed flow‐induced atherosclerosis. Piezo1 was shown to facilitate calcium ions (Ca 2 + ) influx in response to OSS, thereby activating endothelial inflammation. This inflammatory response was attenuated in the absence of Piezo1. Additionally, we identified that under OSS, Piezo1 activates the Ca 2 + /CaM/CaMKII (calmodulin/calmodulin‐dependent protein kinases Ⅱ) pathways, which subsequently stimulate downstream kinases FAK (focal adhesion kinase) and Src. This leads to the activation of the OSS‐sensitive YAP (yes‐associated protein), ultimately triggering endothelial inflammation. Conclusions: Our study highlights the key role of Piezo1 in atherosclerotic endothelial inflammation, proposing the Piezo1–Ca 2+ /CaM/CaMKII‐FAK/Src‐YAP axis as a previously unknown endothelial mechanotransduction pathway. Piezo1 is expected to become a potential therapeutic target for atherosclerosis and cardiovascular diseases.
- 25 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e035558
Top Cited PapersOpen AccessPiezo1‐Mediated Mechanotransduction Contributes to Disturbed Flow‐Induced Atherosclerotic Endothelial Inflammation
Background: Disturbed flow generates oscillatory shear stress (OSS), which in turn leads to endothelial inflammation and atherosclerosis. Piezo1, a biomechanical force sensor, plays a crucial role in the cardiovascular system. However, the specific role of Piezo1 in atherosclerosis remains to be fully elucidated. Methods and Results: We detected the expression of Piezo1 in atherosclerotic mice and endothelial cells from regions with disturbed blood flow. The pharmacological inhibitor Piezo1 inhibitor (GsMTx4) was used to evaluate the impact of Piezo1 on plaque progression and endothelial inflammation. We examined Piezo1's direct response to OSS in vitro and its effects on endothelial inflammation. Furthermore, mechanistic studies were conducted to explore the potential molecular cascade through which Piezo1 mediates endothelial inflammation in response to OSS. Our findings revealed the upregulation of Piezo1 in apoE−/− (apolipoprotein E) atherosclerotic mice, which is associated with disturbed flow. Treatment with GsMTx4 not only delayed plaque progression but also mitigated endothelial inflammation in both chronic and disturbed flow‐induced atherosclerosis. Piezo1 was shown to facilitate calcium ions (Ca 2 + ) influx in response to OSS, thereby activating endothelial inflammation. This inflammatory response was attenuated in the absence of Piezo1. Additionally, we identified that under OSS, Piezo1 activates the Ca 2 + /CaM/CaMKII (calmodulin/calmodulin‐dependent protein kinases Ⅱ) pathways, which subsequently stimulate downstream kinases FAK (focal adhesion kinase) and Src. This leads to the activation of the OSS‐sensitive YAP (yes‐associated protein), ultimately triggering endothelial inflammation. Conclusions: Our study highlights the key role of Piezo1 in atherosclerotic endothelial inflammation, proposing the Piezo1–Ca 2+ /CaM/CaMKII‐FAK/Src‐YAP axis as a previously unknown endothelial mechanotransduction pathway. Piezo1 is expected to become a potential therapeutic target for atherosclerosis and cardiovascular diseases.
- 1 April 2005
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 288 (4) , L734-L740
Activation of proteinase-activated receptor-2 in mesothelial cells induces pleural inflammation
Pleural inflammation underlies many pleural diseases, but its pathogenesis remains unclear. Proteinase-activated receptor-2 (PAR2) is a novel seven-transmembrane receptor with immunoregulatory roles. We hypothesized that PAR2is present on mesothelial cells and can induce pleural inflammation. PAR2was detected by immunohistochemistry in all (19 parietal and 11 visceral) human pleural biopsies examined. In cultured murine mesothelial cells, a specific PAR2-activating peptide (SLIGRL-NH2) at 10, 100, and 1,000 μM stimulated a 3-, 42-, and 1,330-fold increase of macrophage inflammatory protein (MIP)-2 release relative to medium control, respectively ( P < 0.05 all) and a 2-, 32-, and 75-fold rise over the control peptide (LSIGRL-NH2, P < 0.05 all). A similar pattern was seen for TNF-α release. Known physiological activators of PAR2, tryptase, trypsin, and coagulation factor Xa, also stimulated dose-dependent MIP-2 release from mesothelial cells in vitro. Dexamethasone inhibited the PAR2-mediated MIP-2 release in a dose-dependent manner. In vivo, pleural fluid MIP-2 levels in C57BL/6 mice injected intrapleurally with SLIGRL-NH2(10 mg/kg) were significantly higher than in mice injected with LSIGRL-NH2or PBS (2,710 ± 165 vs. 880 ± 357 vs. 88 ± 46 pg/ml, respectively; P < 0.001). Pleural fluid neutrophil counts were higher in SLIGRL-NH2group than in the LSIGRL-NH2and PBS groups (by 40- and 26-fold, respectively; P < 0.05). This study establishes that activation of mesothelial cell PAR2potently induces the release of inflammatory cytokines in vitro and neutrophil recruitment into the pleural cavity in vivo.
- 1 April 2005
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 288 (4) , L734-L740
Activation of proteinase-activated receptor-2 in mesothelial cells induces pleural inflammation
Pleural inflammation underlies many pleural diseases, but its pathogenesis remains unclear. Proteinase-activated receptor-2 (PAR2) is a novel seven-transmembrane receptor with immunoregulatory roles. We hypothesized that PAR2is present on mesothelial cells and can induce pleural inflammation. PAR2was detected by immunohistochemistry in all (19 parietal and 11 visceral) human pleural biopsies examined. In cultured murine mesothelial cells, a specific PAR2-activating peptide (SLIGRL-NH2) at 10, 100, and 1,000 μM stimulated a 3-, 42-, and 1,330-fold increase of macrophage inflammatory protein (MIP)-2 release relative to medium control, respectively ( P < 0.05 all) and a 2-, 32-, and 75-fold rise over the control peptide (LSIGRL-NH2, P < 0.05 all). A similar pattern was seen for TNF-α release. Known physiological activators of PAR2, tryptase, trypsin, and coagulation factor Xa, also stimulated dose-dependent MIP-2 release from mesothelial cells in vitro. Dexamethasone inhibited the PAR2-mediated MIP-2 release in a dose-dependent manner. In vivo, pleural fluid MIP-2 levels in C57BL/6 mice injected intrapleurally with SLIGRL-NH2(10 mg/kg) were significantly higher than in mice injected with LSIGRL-NH2or PBS (2,710 ± 165 vs. 880 ± 357 vs. 88 ± 46 pg/ml, respectively; P < 0.001). Pleural fluid neutrophil counts were higher in SLIGRL-NH2group than in the LSIGRL-NH2and PBS groups (by 40- and 26-fold, respectively; P < 0.05). This study establishes that activation of mesothelial cell PAR2potently induces the release of inflammatory cytokines in vitro and neutrophil recruitment into the pleural cavity in vivo.